ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study

Zheng, Xinlong; Zhang, Longfeng; Wu, Lin; Zhao, Jun; Sun, Jianguo; Fang, Yong; Zhou, Jin; Chu, Qian; Shen, Yihong; Yang, Zhenzhou; Chen, Lijin; Huang, Meijuan; Lin, Xiaoyan; Liu, Zhenhua; Shen, Peng; Wang, Zhijie; Wang, Xin; Wang, Huijuan; Han, Zhengbo; Liu, Anwen; Zhang, Hongmei; Ye, Feng; Gao, Wen; Wu, Fang; Song, Zhengbo; Chen, Shengchi; Zhou, Chenzhi; Wang, Qian; Xu, Chunwei; Huang, Dingzhi; Zheng, Xiaobin; Miao, Qian; Jiang, Kan; Xu, Yiquan; Wu, Shiwen; Wang, Haibo; Zhang, Qiuyu电子科技大学; 福州大学; 广州医学院; 华中科技大学; 南昌大学; 南方医科大学; 南京大学; 四川大学; 浙江大学; 郑州大学; 厦门大学; 中国医科大学; 中国医学科学院; 中国科学院研究生院; 中国医学科学院北京协和医院; 1
BMC CANCER2023-12-16DOI: 10.1186/s12885-023-11737-x
16阅读
引用收藏
分享

摘要

AimsTo investigate the predictive value of baseline C-reactive protein (CRP) levels on the efficacy of chemotherapy plus immune checkpoint inhibitors (ICI) in patients with advanced lung squamous cell carcinoma (LSCC).Materials and methodsIn this retrospective multicenter study spanning from January 2016 to December 2020, advanced LSCC patients initially treated with chemotherapy or a combination of chemotherapy and ICI were categorized into normal and elevated CRP subgroups. The relationship between CRP levels and treatment outcomes was analyzed using multivariate Cox proportional hazards models and multivariate logistic regression, focusing primarily on the progression-free survival (PFS) endpoint, and secondarily on overall survival (OS) and objective response rate (ORR) endpoints. Survival curves were generated using the Kaplan-Meier method, with the log-rank test used for comparison between groups.ResultsOf the 245 patients evaluated, the 105 who received a combination of chemotherapy and ICI with elevated baseline CRP levels exhibited a significant reduction in PFS (median 6.5 months vs. 11.8 months, HR, 1.78; 95% CI: 1.12-2.81; p = 0.013) compared to those with normal CRP levels. Elevated CRP was identified as an independent risk factor for poor PFS through multivariate-adjusted analysis. However, among the 140 patients receiving chemotherapy alone, baseline CRP levels did not significantly influence PFS. Furthermore, within the combination therapy group, there was a notable decrease in the ORR (51% vs. 71%, p = 0.035), coupled with a significantly shorter OS (median 20.9 months vs. 31.5 months, HR, 2.24; 95% CI: 1.13-4.44; p = 0.033).ConclusionIn patients with advanced LSCC, elevated baseline CRP levels were identified as an independent predictive factor for the efficacy of combination therapy with chemotherapy and ICI, but not in chemotherapy alone. This suggests that CRP may be a valuable biomarker for guiding treatment strategies.

学科与关键词

关键词
Lung squamous cell carcinomaImmune checkpoint inhibitorsC-reactive proteinPredictive biomarker
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
BMC CANCER
发表日期
2023-12-16
卷期
第 23 卷, 第 1 期
页码
1244
DOI
10.1186/s12885-023-11737-x
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82372954, 82072565]; Fujian Provincial Health Systemic Innovation Project [2020CXA010]; Fujian provincial health technology project [2020QNA014]; Scientific and technological innovation joint capital projects of Fujian Province [2020Y9038]; Beijing Xisike Clinical Oncology Research Foundation [Y-2019AZZD-0386]

作者

  • Z

    Zheng, Xinlong (第一作者)

    fujian canc hosp · fujian med univ

  • Z

    Zhang, Longfeng

    fujian canc hosp · fujian med univ

查看全部 41 位作者收起作者
  • W

    Wu, Lin

    2 · hunan canc hosp

  • Z

    Zhao, Jun

    peking univ canc hosp & inst

  • S

    Sun, Jianguo

    xinqiao hosp

  • F

    Fang, Yong

    zhejiang univ

  • Z

    Zhou, Jin

    sichuan canc hosp & inst · univ elect sci & technol china

  • C

    Chu, Qian

    huazhong univ sci & technol

  • S

    Shen, Yihong

    1 · zhejiang univ

  • Y

    Yang, Zhenzhou

    2 · chongqing med univ

  • C

    Chen, Lijin

    fujian med univ

  • H

    Huang, Meijuan

    sichuan univ

  • L

    Lin, Xiaoyan

    fujian med univ

  • L

    Liu, Zhenhua

    fujian med univ · fujian prov hosp

  • S

    Shen, Peng

    southern med univ

  • W

    Wang, Zhijie

    chinese acad med sci · peking union med coll

  • W

    Wang, Xin

    xiamen univ

  • W

    Wang, Huijuan

    zhengzhou univ

  • H

    Han, Zhengbo

    china med univ

  • L

    Liu, Anwen

    nanchang univ

  • Z

    Zhang, Hongmei

  • Y

    Ye, Feng

    1 · fujian med univ · xiamen univ

  • G

    Gao, Wen

    nanjing med univ

  • W

    Wu, Fang

    2

  • S

    Song, Zhengbo

    univ chinese acad sci · zhejiang canc hosp

  • C

    Chen, Shengchi

    1 · fujian med univ

  • Z

    Zhou, Chenzhi

    guangzhou med univ

  • W

    Wang, Qian

    nanjing univ chinese med

  • X

    Xu, Chunwei

    nanjing univ

  • H

    Huang, Dingzhi

    tianjin med univ canc inst & hosp

  • Z

    Zheng, Xiaobin

    fujian canc hosp · fujian med univ

  • M

    Miao, Qian

    fujian canc hosp · fujian med univ

  • J

    Jiang, Kan

    fujian canc hosp · fujian med univ

  • X

    Xu, Yiquan

    fujian canc hosp · fujian med univ

  • W

    Wu, Shiwen

    fujian canc hosp · fujian med univ

  • W

    Wang, Haibo

    fujian canc hosp · fujian med univ

  • Z

    Zhang, Qiuyu

    fujian med univ

  • Y

    Yang, Shanshan

    fujian canc hosp · fujian med univ

  • L

    Li, Yujing

    fujian canc hosp · fujian med univ

  • C

    Chen, Sihui

    fujian canc hosp · fujian med univ

  • L

    Lin, Gen (通讯)

    fujian canc hosp · fujian med univ · fuzhou univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417